keyword
https://read.qxmd.com/read/38228628/mode-of-progression-in-smoldering-multiple-myeloma-a-study-of-406-patients
#21
JOURNAL ARTICLE
Nadine H Abdallah, Arjun Lakshman, Shaji K Kumar, Joselle Cook, Moritz Binder, Prashant Kapoor, Angela Dispenzieri, Morie A Gertz, Martha Q Lacy, Suzanne R Hayman, Francis K Buadi, David Dingli, Yi Lin, Taxiarchis Kourelis, Rahma Warsame, Leif Bergsagel, S Vincent Rajkumar
The approach to patients with high-risk smoldering multiple myeloma (SMM) varies among clinicians; while some advocate early intervention, others reserve treatment at progression to multiple myeloma (MM). We aimed to describe the myeloma-defining events (MDEs) and clinical presentations leading to MM diagnosis among SMM patients seen at our institution. We included 406 patients diagnosed with SMM between 2013-2022, seen at Mayo Clinic, Rochester, MN. The 2018 Mayo 20/2/20 criteria were used for risk stratification...
January 17, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38214323/from-multiple-myeloma-to-acute-myeloid-leukemia-a-case-report-of-a-61-year-old-woman-after-8-years-of-chemotherapy-and-immunotherapy
#22
REVIEW
Xue-Hang Fu, Rong-Yan Guan, Zoufang Huang, Yun Li, Guang Lu, Wei-Wei Mou, Jun Du
BACKGROUND: As the second most prevalent hematologic malignancy, multiple myeloma (MM) affects plasma cells and is characterized by chromosomal abnormalities, particularly involving the immunoglobulin heavy chain switch region. MM represents a biologically and clinically heterogeneous hematological malignancy that serves as a clonal evolution model, exhibiting clonal heterogeneity throughout all stages from monoclonal gammopathy undetermined significance (MGUS) and smoldering multiple myeloma (SMM) to MM...
2024: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/38203720/the-involvement-of-lag-3-positive-plasma-cells-in-the-development-of-multiple-myeloma
#23
JOURNAL ARTICLE
Natalia Kreiniz, Nasren Eiza, Tamar Tadmor, Ilana Levy Yurkovski, Sarah Matarasso Greenfeld, Adi Sabag, Raeda Mubariki, Celia Suriu, Ekaterina Votinov, Elias Toubi, Zahava Vadasz
The Lymphocyte-Activation Protein 3 (LAG-3) inhibitory receptor is expressed on regulatory plasma cells (PCs). Micro-environmental cells that express LAG-3 were found to be increased during the progression of smoldering multiple myeloma (SMM). To assess the possible role of LAG-3 expression on regulatory PCs in patients with plasma cell dyscrasia. Purified Cluster of Differentiation 138 (CD138+) PCs from patients with premalignant conditions, active multiple myeloma (MM), and controls were analyzed for the expression of LAG-3 by flow cytometry...
December 31, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/38199896/molecular-pathogenesis-of-multiple-myeloma-clinical-implications
#24
REVIEW
Francesco Maura, Peter Leif Bergsagel
Multiple myeloma is a malignancy of bone-marrow-localized, isotype-switched plasma cells that secrete a monoclonal immunoglobulin and cause hyperCalcemia, Anemia, Renal failure, and lytic Bone disease. It is preceded, often for decades, by a relatively stable monoclonal gammopathy lacking these clinical and malignant features. Both conditions are characterized by the presence of types of immunoglobulin heavy gene translocations that dysregulate a cyclin D family gene on 11q13 (CCND1), 6p21 (CCND3), or 12q11 (CCND2), a maf family gene on 16q23 (MAF), 20q11 (MAFB), or 8q24 (MAFA), or NSD2/FGFR3 on 4p16, or the presence of hyperdiploidy...
April 2024: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/38175579/screening-in-multiple-myeloma-and-its-precursors-are-we-there-yet
#25
REVIEW
Sæmundur Rögnvaldsson, Sigrún Thorsteinsdóttir, Sigurður Yngvi Kristinsson
BACKGROUND: Multiple myeloma (MM) is a hematological malignancy that develops over years from the asymptomatic precursors, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. Recent evidence shows that by initiating treatment at an asymptomatic stage, outcomes in MM can be significantly improved. However, a vast majority of MM patients are diagnosed after the development of symptomatic end-organ damage and cannot reap the benefits of early treatment. The precursors of MM are easily detected by serum protein electrophoresis and free light chain assay of the serum, raising the question of whether population-based screening could detect MM at an asymptomatic stage and significantly expand the availability of early treatment in MM...
January 4, 2024: Clinical Chemistry
https://read.qxmd.com/read/38166067/acquired-von-willebrand-s-syndrome-in-a-patient-with-concomitant-chronic-lymphocytic-lymphoma-and-smoldering-multiple-myeloma
#26
JOURNAL ARTICLE
Nirav Haribhakti, Hyun Lee, Matthew Quesenberry, John Reagan
An African-American female in her sixties presented to the hospital with intermittent gum bleeding for the past two years along with severe anemia. This case details the differential and workup that lead to the diagnosis of acquired von Willebrand's syndrome (AvWS). A thorough investigation in the possible etiologies of AvWS revealed that the patient had concomitant chronic lymphocytic lymphoma (CLL) and smoldering multiple myeloma (SMM). Due to the concomitant diagnosis of CLL and SMM, there was a dilemma regarding whether CLL, SMM, or both was driving this patient's AvWS...
January 4, 2024: Rhode Island Medical Journal
https://read.qxmd.com/read/38158241/smoldering-multiple-myeloma-observation-versus-control-versus-cure
#27
REVIEW
S Vincent Rajkumar, P Leif Bergsagel, Shaji Kumar
Smoldering multiple myeloma (SMM) is an intermediate clinical stage in the spectrum of monoclonal plasma cell disorders. It represents a heterogeneous clinically defined condition in which some patients (approximately 50%) have monoclonal gammopathy of undetermined significance (premalignancy), and some (approximately 50%) have multiple myeloma (biologic malignancy). Using specific prognostic factors, patients with SMM, in whom malignant transformation has already likely occurred, can be identified. These patients are considered to have high-risk SMM...
December 28, 2023: Hematology/oncology Clinics of North America
https://read.qxmd.com/read/38095141/immunoglobulin-light-chain-amyloidosis-2024-update-on-diagnosis-prognosis-and-treatment
#28
JOURNAL ARTICLE
Morie A Gertz
DISEASE OVERVIEW: Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues. Clinical features depend on organs involved but can include heart failure with preserved ejection fraction, nephrotic syndrome, hepatic dysfunction, peripheral/autonomic neuropathy, and "atypical smoldering multiple myeloma or MGUS." DIAGNOSIS: Tissue biopsy stained with Congo red demonstrating amyloid deposits with apple-green birefringence is required for the diagnosis of AL amyloidosis...
February 2024: American Journal of Hematology
https://read.qxmd.com/read/38072838/immunophenotypic-assessment-of-clonal-plasma-cells-and-b-cells-in-bone-marrow-and-blood-in-the-diagnostic-classification-of-early-stage-monoclonal-gammopathies-an-istopmm-study
#29
JOURNAL ARTICLE
Oihane Pérez-Escurza, Juan Flores-Montero, Jón Þórir Óskarsson, Luzalba Sanoja-Flores, Julio Del Pozo, Quentin Lecrevisse, Silvia Martín, Elín Ruth Reed, Guðlaug Katrín Hákonardóttir, Stephen Harding, Sigrún Þorsteinsdóttir, Sæmundur Rögnvaldsson, Thorvardur Jon Love, Brian Durie, Sigurður Yngvi Kristinsson, Alberto Orfao
Monoclonal gammopathy of undetermined significance (MGUS) is the earliest discernible stage of multiple myeloma (MM) and Waldenström's macroglobulinemia (WM). Early diagnosis of MG may be compromised by the low-level infiltration, undetectable to low-sensitive methodologies. Here, we investigated the prevalence and immunophenotypic profile of clonal (c) plasma cells (PC) and/or cB-lymphocytes in bone marrow (BM) and blood of subjects with a serum M-component from the iSTOPMM program, using high-sensitive next-generation flow cytometry (NGF), and its utility in the diagnostic classification of early-stage MG...
December 11, 2023: Blood Cancer Journal
https://read.qxmd.com/read/38067393/cytogenetic-profile-in-monoclonal-gammopathy-of-undetermined-significance-smoldering-and-symptomatic-multiple-myeloma-a-study-of-1087-patients-with-highly-purified-plasma-cells
#30
JOURNAL ARTICLE
Guilin Tang, Yilin Wu, Pei Lin, Gokce A Toruner, Shimin Hu, Shaoying Li, Muzaffar H Qazilbash, Robert Z Orlowski, Christine Ye, Jie Xu, Karen A Nahmod, L Jeffrey Medeiros, Zhenya Tang
The aim of this study was to examine the cytogenetic profiles of plasma cell neoplasms (PCNs) at various disease stages, encompassing 1087 patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), newly diagnosed multiple myeloma (NDMM), and refractory/relapsed multiple myeloma (RRMM). Fluorescence in situ hybridization (FISH) analyses were conducted on highly purified plasma cell samples, revealing that 96% of patients exhibited at least one cytogenetic abnormality...
December 2, 2023: Cancers
https://read.qxmd.com/read/38046471/clinician-preferences-on-treatment-of-smoldering-myeloma-a%C3%A2-cross-sectional-survey
#31
JOURNAL ARTICLE
Ghulam Rehman Mohyuddin, Rajshekhar Chakraborty, Edward R Scheffer Cliff, Benjamin A Derman
BACKGROUND: Smoldering myeloma (SMM) is an asymptomatic precursor condition to multiple myeloma (MM) with a variable risk of progression. The management of high-risk SMM (HR-SMM) remains controversial, particularly with changes in diagnostic criteria that led to reclassifying of some patients with SMM to MM. This study aimed to assess clinician preferences for whether to treat patients with HR-SMM and/or patients with MM diagnosed solely by SLiM criteria (free light chain ratio >100, bone marrow plasma cell percentage >60, greater than two focal marrow lesions on MRI) through an electronic survey...
November 2023: EClinicalMedicine
https://read.qxmd.com/read/38022528/determination-of-the-target-of-monoclonal-immunoglobulins-a-novel-diagnostic-tool-for-individualized-mgus-therapy-and-prevention-and-therapy-of-smoldering-and-multiple-myeloma
#32
REVIEW
Sylvie Hermouet, Edith Bigot-Corbel, Jean Harb
Subsets of patients diagnosed with a monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM) or multiple myeloma (MM), present with a monoclonal immunoglobulin (Ig) specific for an infectious pathogen, including hepatitis C and B viruses (HCV, HBV), Helicobacter pylori and several Herpesviruses . Such cases are likely initiated by infection, since in the context of HCV- or HBV-infected patients, antiviral therapy can lead to the disappearance of antigenic stimulation, control of clonal plasma cells, and reduced or suppressed monoclonal Ig production...
2023: Frontiers in Immunology
https://read.qxmd.com/read/37994080/t-11-14-status-is-stable-between-diagnosis-and-relapse-and-concordant-between-detection-methodologies-based-on-fluorescence-in-situ-hybridization-and-next-generation-sequencing-in-patients-with-multiple-myeloma
#33
JOURNAL ARTICLE
Hervé Avet-Loiseau, Raphaële Thiébaut-Millot, Xiaotong Li, Jeremy A Ross, Carlos Hader
Multiple myeloma (MM) is associated with a wide variety of recurrent genomic alterations. The most common translocation in MM is t(11;14). In this retrospective, single-center, non-interventional study, patient bone marrow samples were examined at diagnosis and at relapse(s) following treatment with anti-myeloma regimens to determine whether t(11;14) status was stable over time. This Stability Cohort consisted of 272 patients, of whom 118 were t(11;14)-positive at diagnosis and 154 were negative. All patients in the Stability Cohort retained the same t(11;14) status at relapse that they had at diagnosis of MM...
November 23, 2023: Haematologica
https://read.qxmd.com/read/37961238/mode-of-progression-in-smoldering-multiple-myeloma-a-study-of-406-patients
#34
S Rajkumar, Nadine Abdallah, Arjun Lakshman, Shaji Kumar, Joselle Cook, Moritz Binder, Prashant Kapoor, Angela Dispenzieri, Morie Gertz, Martha Lacy, Suzanne Hayman, Francis Buadi, David Dingli, Yi Lin, Taxiarchis Kourelis, Rahma Warsame, P Leif Bergsagel
The approach to patients with high-risk smoldering multiple myeloma (SMM) varies among clinicians; while some advocate early intervention, others reserve treatment at progression to multiple myeloma (MM). We aimed to describe the myeloma-defining events (MDEs) and clinical presentations leading to MM diagnosis among SMM patients seen at our institution. We included 406 patients diagnosed with SMM between 2013-2022, seen at Mayo Clinic, Rochester, MN. The 2018 Mayo 20/2/20 criteria were used for risk stratification...
October 23, 2023: Research Square
https://read.qxmd.com/read/37958428/non-toxicological-role-of-aryl-hydrocarbon-receptor-in-obesity-associated-multiple-myeloma-cell-growth-and-survival
#35
JOURNAL ARTICLE
Jonathan D Diedrich, Craig E Cole, Matthew J Pianko, Justin A Colacino, Jamie J Bernard
Obesity is not only a risk factor for multiple myeloma (MM) incidence, but it is also associated with an increased risk of progression from myeloma precursors-monoclonal gammopathy of undetermined significance-and smoldering myeloma. Adipocytes in the bone marrow (BMAs) microenvironment have been shown to facilitate MM cell growth via secreted factors, but the nature of these secreted factors and their mechanism of action have not been fully elucidated. The elevated expression of aryl hydrocarbon receptor (AhR) is associated with a variety of different cancers, including MM; however, the role of AhR activity in obesity-associated MM cell growth and survival has not been explored...
November 1, 2023: Cancers
https://read.qxmd.com/read/37936979/a-rare-coexistence-of-multiple-myeloma-and-polycythemia-vera
#36
Alexander Landsman, Priyanka Barua, Alida Podrumar
Multiple myeloma (MM) is classically associated with organ dysfunction leading to hypercalcemia, renal insufficiency, anemia and bone disease, known as the CRAB criteria. More than 70% of patients with MM present with anemia. Few rare case reports, however, have demonstrated the presentation of MM associated with polycythemia. We present an interesting case of a 65-year-old female who was initially diagnosed with monoclonal gammopathy of undetermined significance (MGUS) which progressed to smoldering myeloma and later developed into MM...
October 2023: Journal of Hematology (Brossard, Quebec)
https://read.qxmd.com/read/37822056/multiple-myeloma-and-its-treatment-contribute-to-increased-platelet-reactivity
#37
JOURNAL ARTICLE
Joanne L Mitchell, Dalia Khan, Rekha H Rana, Neline Kriek, Amanda J Unsworth, Tanya Sage, Alexander P Bye, Michael Laffan, Susan Shapiro, Anjan Thakurta, Henri Grech, Karthik Ramasamy, Jonathan M Gibbins
Multiple myeloma (MM) and its precursor states, smoldering myeloma (SM) and monoclonal gammopathy of undetermined significance (MGUS) are associated with increased incidence of thrombosis, however the cause of this is unknown. Lenalidomide treatment of MM substantially improves patient survival, although significantly increases thrombotic risk by an unknown mechanism. This pilot study aimed to establish the impact of MM and its treatment with Lenalidomide on platelet function. We analyzed platelet function in MGUS, SM and MM compared to healthy controls...
December 2023: Platelets
https://read.qxmd.com/read/37818527/failure-to-confirm-typical-echocardiographic-findings-of-cardiac-amyloidosis-in-an-unresolved-nonischemic-cardiomyopathy-associated-with-smoldering-multiple-myeloma-a-case-report
#38
Carlos Gaibor, Endurance Evbayekha, Brittany Dixon
Amyloidosis is a leading cause of infiltrative cardiomyopathy and in turn heart failure with preserved ejection fraction. Amyloidosis is mainly classified into amyloid light chain (AL) or primary amyloidosis and transthyretin amyloidosis (ATTR) that is subdivided into wild-type ATTR (ATTRwt) and hereditary or familial transthyretin-related amyloidosis (hATTR). Moreover, strain preservation pattern in the left ventricular apex in echocardiography suggests cardiac amyloidosis and cardiac magnetic resonance (CMR) could identify an infiltrative process...
September 2023: Curēus
https://read.qxmd.com/read/37759449/gper1-activation-exerts-anti-tumor-activity-in-multiple-myeloma
#39
JOURNAL ARTICLE
Maria Eugenia Gallo Cantafio, Roberta Torcasio, Francesca Scionti, Maria Mesuraca, Domenica Ronchetti, Mariaelena Pistoni, Dina Bellizzi, Giuseppe Passarino, Eugenio Morelli, Antonino Neri, Giuseppe Viglietto, Nicola Amodio
G protein-coupled estrogen receptor 1 (GPER1) activation is emerging as a promising therapeutic strategy against several cancer types. While GPER targeting has been widely studied in the context of solid tumors, its effect on hematological malignancies remains to be fully understood. Here, we show that GPER1 mRNA is down-regulated in plasma cells from overt multiple myeloma (MM) and plasma cell leukemia patients as compared to normal donors or pre-malignant conditions (monoclonal gammopathy of undetermined significance and smoldering MM); moreover, lower GPER1 expression associates with worse overall survival of MM patients...
September 7, 2023: Cells
https://read.qxmd.com/read/37752128/clinical-characteristics-and-outcomes-in-risk-stratified-patients-with-smoldering-multiple-myeloma-data-from-the-czech-republic-registry-of-monoclonal-gammopathies
#40
JOURNAL ARTICLE
Viera Sandecka, Tereza Popkova, Martin Stork, Vladimir Maisnar, Jiri Minarik, Alexandra Jungova, Petr Pavlicek, Lukas Stejskal, Lenka Pospisilova, Adriana Heindorfer, Jarmila Obernauerova, Evzen Gregora, Michal Sykora, Jana Ullrychova, Marek Wrobel, Petr Kessler, Tomas Jelinek, Peter Kunovszki, Sacheeta Bathija, Blanca Gros, Sabine Wilbertz, Qian Cai, Annette Lam, Ivan Spicka
Smoldering multiple myeloma (SMM) is an asymptomatic precursor to active multiple myeloma (MM). The aim of this study was to report clinical characteristics and outcomes of patients with SMM stratified based on their risk of progression to MM using the Mayo 20/2/20 criteria. Data were leveraged from the Czech Myeloma Group Registry of Monoclonal Gammopathies (RMG). Key outcomes included progression-free survival from SMM diagnosis to active MM diagnosis or death (PFS), progression-free survival from SMM diagnosis to progression on first line (1 L) MM treatment or death (PFS2), and overall survival (OS)...
September 27, 2023: Blood Cancer Journal
keyword
keyword
111891
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.